公开(公告)号：US20170360935A1

公开(公告)日：2017-12-21

申请号：US15534999

申请日：2015-12-10

Applicant: Pfizer Inc.

Inventor： Kevin Richard Back ,  Michael Cram ,  Aidan James Harper ,  W. James Huang ,  Jonathan Richard Lillis ,  Timothy Michael Lukas ,  Sumit Luthra

IPC: A61K47/12 ,  A61K9/19 ,  A61K9/08 ,  A61K47/02 ,  C07D401/12 ,  A61K47/26

CPC classification number: A61K47/12 ,  A61K9/0019 ,  A61K9/08 ,  A61K9/19 ,  A61K31/5377 ,  A61K47/02 ,  A61K47/26 ,  C07B2200/13 ,  C07D401/12

Abstract: The present invention relates to a pharmaceutical aqueous formulation comprising -(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-,3,5-triazin-2-yl)phenyl]urea, or a pharmaceutically acceptable salt thereof, that is a clear solution. Such a formulation is particularly suitable for intravenous or parenteral administration to a patient.

公开(公告)号：US20130203767A1

公开(公告)日：2013-08-08

申请号：US13826769

申请日：2013-03-14

Applicant: Pfizer Inc.

Inventor： Ghazwan Saleem Butrous ,  Timothy Michael Lukas ,  Ian Machin

IPC: A61K31/519

CPC classification number: A61K31/519 ,  A61K31/496 ,  A61K31/501 ,  A61K31/517 ,  A61K31/53

Abstract: This invention relates to the use of certain cyclic guanosine 3′,5′-monophosphate phosphodiesterase type five (cGMP PDE5) inhibitors, including in particular the compound sildenafil, for the treatment of pulmonary hypertension.

公开(公告)号：US10660959B2

公开(公告)日：2020-05-26

申请号：US16189009

申请日：2018-11-13

Applicant: Pfizer Inc.

Inventor： Kevin Richard Back ,  Michael Cram ,  Aidan James Harper ,  W. James Huang ,  Jonathan Richard Lillis ,  Timothy Michael Lukas ,  Sumit Luthra

IPC: A61K47/12 ,  C07D401/12 ,  A61K9/00 ,  A61K47/26 ,  A61K9/08 ,  A61K9/19 ,  A61K31/5377 ,  A61K47/02

Abstract: The present invention relates to a pharmaceutical aqueous formulation comprising 1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea, or a pharmaceutically acceptable salt thereof, that is a clear solution. Such a formulation is particularly suitable for intravenous or parenteral administration to a patient.

公开(公告)号：US20190105390A1

公开(公告)日：2019-04-11

申请号：US16189009

申请日：2018-11-13

Applicant: Pfizer Inc.

Inventor： Kevin Richard Back ,  Michael Cram ,  Aidan James Harper ,  W. James Huang ,  Jonathan Richard Lillis ,  Timothy Michael Lukas ,  Sumit Luthra

IPC: A61K47/12 ,  A61K31/5377 ,  C07D401/12 ,  A61K47/26 ,  A61K9/00 ,  A61K47/02 ,  A61K9/19 ,  A61K9/08

Abstract: The present invention relates to a pharmaceutical aqueous formulation comprising 1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea, or a pharmaceutically acceptable salt thereof, that is a clear solution. Such a formulation is particularly suitable for intravenous or parenteral administration to a patient.

公开(公告)号：US10172942B2

公开(公告)日：2019-01-08

申请号：US15534999

申请日：2015-12-10

Applicant: Pfizer Inc.

Inventor： Kevin Richard Back ,  Michael Cram ,  Aidan James Harper ,  W. James Huang ,  Jonathan Richard Lillis ,  Timothy Michael Lukas ,  Sumit Luthra

IPC: A61K47/12 ,  A61K47/26 ,  A61K47/02 ,  A61K9/00 ,  A61K9/08 ,  A61K9/19 ,  A61K31/5377 ,  C07D401/12

Abstract: The present invention relates to a pharmaceutical aqueous formulation comprising -(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-,3,5-triazin-2-yl)phenyl]urea, or a pharmaceutically acceptable salt thereof, that is a clear solution. Such a formulation is particularly suitable for intravenous or parenteral administration to a patient.